Physician profile
Wesley King
NPI 1538376314
$166,845.73
in general payments reported to CMS, 2019-2025
48 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $32K · 2021: $31K · 2022: $43K · 2023: $12K · 2024: $16K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $12K · Consulting Fee: $1,525 · Travel and Lodging: $72.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,137.50 |
| Food and Beverage | $11,864.85 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $72.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,240.37 | 2021-2025 | |
| Lilly USA, LLC | $55,158.96 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $18,132.81 | 2023-2025 | |
| Allergan, INC. | $11,285.01 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $6,299.65 | 2022 | |
| Ucb, INC. | $2,004.18 | 2019-2024 | Briviact, Nayzilam |
| Lundbeck LLC | $1,332.96 | 2020-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $1,328.38 | 2021-2025 | Ingrezza, Ongentys |
| Amgen INC. | $1,267.71 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $1,249.13 | 2019-2025 | Ajovy, Austedo Xr |
| Sk Life Science, INC. | $1,055.20 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $683.16 | 2019-2024 | Qelbree, Oxtellar Xr |
| Acorda Therapeutics, INC | $599.13 | 2019-2024 | Inbrija, Ampyra |
| Novartis Pharmaceuticals Corporation | $586.90 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $516.75 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.